Potential coverage of a multivalent M protein-based group A streptococcal vaccine

James Dale, Thomas A. Penfound, Boubou Tamboura, Samba O. Sow, James P. Nataro, Milagritos Tapia, Karen L. Kotloff

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. Methods: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. Results: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections. Conclusions: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.

Original languageEnglish (US)
Pages (from-to)1576-1581
Number of pages6
JournalVaccine
Volume31
Issue number12
DOIs
StatePublished - Mar 15 2013

Fingerprint

Streptococcal Vaccines
Vaccines
vaccines
Rheumatic Heart Disease
heart diseases
Streptococcal Infections
Proteins
Rheumatic Fever
proteins
fever
infection
Mali
school children
Pharyngitis
type collections
morbidity
antiserum
epidemiology
Immune Sera
serotypes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Dale, J., Penfound, T. A., Tamboura, B., Sow, S. O., Nataro, J. P., Tapia, M., & Kotloff, K. L. (2013). Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine, 31(12), 1576-1581. https://doi.org/10.1016/j.vaccine.2013.01.019

Potential coverage of a multivalent M protein-based group A streptococcal vaccine. / Dale, James; Penfound, Thomas A.; Tamboura, Boubou; Sow, Samba O.; Nataro, James P.; Tapia, Milagritos; Kotloff, Karen L.

In: Vaccine, Vol. 31, No. 12, 15.03.2013, p. 1576-1581.

Research output: Contribution to journalArticle

Dale, J, Penfound, TA, Tamboura, B, Sow, SO, Nataro, JP, Tapia, M & Kotloff, KL 2013, 'Potential coverage of a multivalent M protein-based group A streptococcal vaccine', Vaccine, vol. 31, no. 12, pp. 1576-1581. https://doi.org/10.1016/j.vaccine.2013.01.019
Dale J, Penfound TA, Tamboura B, Sow SO, Nataro JP, Tapia M et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine. 2013 Mar 15;31(12):1576-1581. https://doi.org/10.1016/j.vaccine.2013.01.019
Dale, James ; Penfound, Thomas A. ; Tamboura, Boubou ; Sow, Samba O. ; Nataro, James P. ; Tapia, Milagritos ; Kotloff, Karen L. / Potential coverage of a multivalent M protein-based group A streptococcal vaccine. In: Vaccine. 2013 ; Vol. 31, No. 12. pp. 1576-1581.
@article{1201376472f0486cb40986c769370340,
title = "Potential coverage of a multivalent M protein-based group A streptococcal vaccine",
abstract = "Background: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. Methods: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. Results: Single isolates representing 42 of 67 emm-types, accounting for 85{\%} of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50{\%}) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60{\%} of the total emm-types recovered in Bamako, which accounted for 81{\%} of all infections. Conclusions: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.",
author = "James Dale and Penfound, {Thomas A.} and Boubou Tamboura and Sow, {Samba O.} and Nataro, {James P.} and Milagritos Tapia and Kotloff, {Karen L.}",
year = "2013",
month = "3",
day = "15",
doi = "10.1016/j.vaccine.2013.01.019",
language = "English (US)",
volume = "31",
pages = "1576--1581",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Potential coverage of a multivalent M protein-based group A streptococcal vaccine

AU - Dale, James

AU - Penfound, Thomas A.

AU - Tamboura, Boubou

AU - Sow, Samba O.

AU - Nataro, James P.

AU - Tapia, Milagritos

AU - Kotloff, Karen L.

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Background: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. Methods: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. Results: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections. Conclusions: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.

AB - Background: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD. Methods: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako. Results: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections. Conclusions: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84875271992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875271992&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.01.019

DO - 10.1016/j.vaccine.2013.01.019

M3 - Article

VL - 31

SP - 1576

EP - 1581

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -